Parsons Capital Management Inc. RI decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 0.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 135,562 shares of the company’s stock after selling 1,051 shares during the quarter. Johnson & Johnson makes up 2.1% of Parsons Capital Management Inc. RI’s investment portfolio, making the stock its 5th biggest holding. Parsons Capital Management Inc. RI’s holdings in Johnson & Johnson were worth $17,624,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Harding Loevner LP acquired a new position in Johnson & Johnson in the second quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. Lenox Wealth Advisors Inc. lifted its holdings in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the period. IHT Wealth Management LLC lifted its holdings in Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson in the second quarter valued at $124,000. 65.70% of the stock is currently owned by institutional investors.

Johnson & Johnson (JNJ) opened at $143.97 on Thursday. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $145.68. The firm has a market cap of $386,780.00, a PE ratio of 24.99, a PEG ratio of 2.67 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the prior year, the business earned $1.68 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. sell-side analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.33%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

JNJ has been the topic of several recent analyst reports. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a report on Monday, September 18th. Goldman Sachs Group lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their target price for the company from $125.00 to $130.00 in a report on Wednesday, September 20th. Citigroup initiated coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They issued a “neutral” rating and a $140.00 target price on the stock. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. Finally, UBS Group restated a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a report on Saturday, September 30th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $145.52.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/parsons-capital-management-inc-ri-has-17-62-million-position-in-johnson-johnson-jnj/1802539.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.